Skip to main content
OpenTrials
Completed

NCT Number: NCT05206149

Stimulation Test With Intranasal Glucagon for Corticotroph, Somatotroph and Antidiuretic Axes

The diagnosis of secondary hypoadrenalism and GH deficiency (GHD) often requires the performance of a dynamic test. The glucagon stimulation test (GST) is one of the options for evaluating hypothalamic-pituitary function, representing a stimulus for both the corticotropic and somatotropic axis, substantially safe and easily available. The standard procedure involves the intramuscular injection of 1-1.5 mg of glucagon based on the patient's weight.

In addition to its antero-pituitary function, glucagon has also shown its ability to stimulate neurohypophyseal secretion. Using the copeptin dosage, it has been shown that after the administration of glucagon in healthy subjects there is a significant release of ADH. However, the available data are scarse and there is no standardized protocol for the use of the glucagon test in diabetes insipidus.

At the moment, GST is not the most frequently chosen diagnostic option. In fact, despite having the advantage of being able to investigate different areas of anterohypophyseal and probably posterohypophyseal function at the same time, the test has some disadvantages: the prolonged duration makes the procedure challenging, the intramuscular injection can be unwelcome, and many variables can come into play in the definition of a normal response (age, BMI, glycemic status).

The recent introduction of a single-dose nasal powder formulation (Baqsimi®) could overcome some of the limitations of classic GST and make the procedure less demanding.

To date, no assessments are yet available regarding a purely diagnostic role in the context of hypopituitarism of this new formulation.

Through the knowledge of the physiological response of the adrenocortical, somatotropic and ADH axis to the administration of intranasal glucagon in healthy subjects, it will be possible to evaluate its possible application in the diagnosis of GH deficiency, central adrenal insufficiency and possibly diabetes insipidus.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Hypopituitarism Brain Diseases Central Nervous System Diseases Endocrine System Diseases Hypothalamic Diseases Nervous System Diseases Pituitary Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

AOU Città della Salute e della Scienza

Turin, Piedmont, 10126, Italy

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Any adult healthy subject (age >= 18 years old) and not meeting the exclusion criteria listed below

Exclusion criteria

  • BMI < 18.5 kg/m2 or > 25 kg/m2
  • Any active pharmacological treatment
  • Pregnancy or breastfeeding

Treatment and study plan

Intranasal glugagon

Drug

Intranasal glucagon is administered at the dose of 3 mg. This corresponds to the administration of a single dose of Baqsimi®.

Other names: Baqsimi®

Intranasal placebo

Drug

Intranasal placebo (represented by isotonic saline solution) is administered.

Primary outcomes

  1. Change in serum ACTH levels between baseline and 15 minutes after glucagon/placebo administration

    Time frame: From baseline (0 minutes) to 15 minutes after glucagon/placebo administration

    The response of the corticotroph axis to the administration of intranasal glucagon, compared to placebo, was evaluated by measuring serum ACTH (ng/L) at baseline (0 minutes) and after 15 minutes from glucagon/placebo administration.

  2. Change in serum ACTH levels between baseline and 30 minutes after glucagon/placebo administration

    Time frame: From baseline (0 minutes) to 30 minutes after glucagon/placebo administration

    The response of the corticotroph axis to the administration of intranasal glucagon, compared to placebo, was evaluated by measuring serum ACTH (ng/L) at baseline (0 minutes) and after 30 minutes from glucagon/placebo administration.

  3. Change in serum ACTH levels between baseline and 45 minutes after glucagon/placebo administration

    Time frame: From baseline (0 minutes) to 45 minutes after glucagon/placebo administration

    The response of the corticotroph axis to the administration of intranasal glucagon, compared to placebo, was evaluated by measuring serum ACTH (ng/L) at baseline (0 minutes) and after 45 minutes from glucagon/placebo administration.

  4. Change in serum ACTH levels between baseline and 60 minutes after glucagon/placebo administration

    Time frame: From baseline (0 minutes) to 60 minutes after glucagon/placebo administration

    The response of the corticotroph axis to the administration of intranasal glucagon, compared to placebo, was evaluated by measuring serum ACTH (ng/L) at baseline (0 minutes) and after 60 minutes from glucagon/placebo administration.

  5. Change in serum ACTH levels between baseline and 75 minutes after glucagon/placebo administration

    Time frame: From baseline (0 minutes) to 75 minutes after glucagon/placebo administration

    The response of the corticotroph axis to the administration of intranasal glucagon, compared to placebo, was evaluated by measuring serum ACTH (ng/L) at baseline (0 minutes) and after 75 minutes from glucagon/placebo administration.

  6. Change in serum ACTH levels between baseline and 90 minutes after glucagon/placebo administration

    Time frame: From baseline (0 minutes) to 90 minutes after glucagon/placebo administration

    The response of the corticotroph axis to the administration of intranasal glucagon, compared to placebo, was evaluated by measuring serum ACTH (ng/L) at baseline (0 minutes) and after 90 minutes from glucagon/placebo administration.

  7. Change in serum ACTH levels between baseline and 120 minutes after glucagon/placebo administration

    Time frame: From baseline (0 minutes) to 120 minutes after glucagon/placebo administration

    The response of the corticotroph axis to the administration of intranasal glucagon, compared to placebo, was evaluated by measuring serum ACTH (ng/L) at baseline (0 minutes) and after 120 minutes from glucagon/placebo administration.

  8. Change in serum ACTH levels between baseline and 150 minutes after glucagon/placebo administration

    Time frame: From baseline (0 minutes) to 150 minutes after glucagon/placebo administration

    The response of the corticotroph axis to the administration of intranasal glucagon, compared to placebo, was evaluated by measuring serum ACTH (ng/L) at baseline (0 minutes) and after 150 minutes from glucagon/placebo administration.

  9. Change in serum ACTH levels between baseline and 180 minutes after glucagon/placebo administration

    Time frame: From baseline (0 minutes) to 180 minutes after glucagon/placebo administration

    The response of the corticotroph axis to the administration of intranasal glucagon, compared to placebo, was evaluated by measuring serum ACTH (ng/L) at baseline (0 minutes) and after 180 minutes from glucagon/placebo administration.

  10. Change in serum cortisol levels between baseline and 15 minutes after glucagon/placebo administration

    Time frame: From baseline (0 minutes) to 15 minutes after glucagon/placebo administration

    The response of the corticotroph axis to the administration of intranasal glucagon, compared to placebo, was evaluated by measuring serum cortisol (µg/L) at baseline (0 minutes) and after 15 minutes from glucagon/placebo administration.

  11. Change in serum cortisol levels between baseline and 30 minutes after glucagon/placebo administration

    Time frame: From baseline (0 minutes) to 30 minutes after glucagon/placebo administration

    The response of the corticotroph axis to the administration of intranasal glucagon, compared to placebo, was evaluated by measuring serum cortisol (µg/L) at baseline (0 minutes) and after 30 minutes from glucagon/placebo administration.

  12. Change in serum cortisol levels between baseline and 45 minutes after glucagon/placebo administration

    Time frame: From baseline (0 minutes) to 45 minutes after glucagon/placebo administration

    The response of the corticotroph axis to the administration of intranasal glucagon, compared to placebo, was evaluated by measuring serum cortisol (µg/L) at baseline (0 minutes) and after 45 minutes from glucagon/placebo administration.

  13. Change in serum cortisol levels between baseline and 60 minutes after glucagon/placebo administration

    Time frame: From baseline (0 minutes) to 60 minutes after glucagon/placebo administration

    The response of the corticotroph axis to the administration of intranasal glucagon, compared to placebo, was evaluated by measuring serum cortisol (µg/L) at baseline (0 minutes) and after 60 minutes from glucagon/placebo administration.

  14. Change in serum cortisol levels between baseline and 75 minutes after glucagon/placebo administration

    Time frame: From baseline (0 minutes) to 75 minutes after glucagon/placebo administration

    The response of the corticotroph axis to the administration of intranasal glucagon, compared to placebo, was evaluated by measuring serum cortisol (µg/L) at baseline (0 minutes) and after 75 minutes from glucagon/placebo administration.

  15. Change in serum cortisol levels between baseline and 90 minutes after glucagon/placebo administration

    Time frame: From baseline (0 minutes) to 90 minutes after glucagon/placebo administration

    The response of the corticotroph axis to the administration of intranasal glucagon, compared to placebo, was evaluated by measuring serum cortisol (µg/L) at baseline (0 minutes) and after 90 minutes from glucagon/placebo administration.

  16. Change in serum cortisol levels between baseline and 120 minutes after glucagon/placebo administration

    Time frame: From baseline (0 minutes) to 120 minutes after glucagon/placebo administration

    The response of the corticotroph axis to the administration of intranasal glucagon, compared to placebo, was evaluated by measuring serum cortisol (µg/L) at baseline (0 minutes) and after 120 minutes from glucagon/placebo administration.

  17. Change in serum cortisol levels between baseline and 150 minutes after glucagon/placebo administration

    Time frame: From baseline (0 minutes) to 150 minutes after glucagon/placebo administration

    The response of the corticotroph axis to the administration of intranasal glucagon, compared to placebo, was evaluated by measuring serum cortisol (µg/L) at baseline (0 minutes) and after 150 minutes from glucagon/placebo administration.

  18. Change in serum cortisol levels between baseline and 180 minutes after glucagon/placebo administration

    Time frame: From baseline (0 minutes) to 180 minutes after glucagon/placebo administration

    The response of the corticotroph axis to the administration of intranasal glucagon, compared to placebo, was evaluated by measuring serum cortisol (µg/L) at baseline (0 minutes) and after 180 minutes from glucagon/placebo administration.

  19. Change in serum GH levels between baseline and 15 minutes after glucagon/placebo administration

    Time frame: From baseline (0 minutes) to 15 minutes after glucagon/placebo administration

    The response of the somatotroph axis to the administration of intranasal glucagon, compared to placebo, was evaluated by measuring serum GH (µg/L) at baseline (0 minutes) and after 15 minutes from glucagon/placebo administration.

  20. Change in serum GH levels between baseline and 30 minutes after glucagon/placebo administration

    Time frame: From baseline (0 minutes) to 30 minutes after glucagon/placebo administration

    The response of the somatotroph axis to the administration of intranasal glucagon, compared to placebo, was evaluated by measuring serum GH (µg/L) at baseline (0 minutes) and after 30 minutes from glucagon/placebo administration.

  21. Change in serum GH levels between baseline and 45 minutes after glucagon/placebo administration

    Time frame: From baseline (0 minutes) to 45 minutes after glucagon/placebo administration

    The response of the somatotroph axis to the administration of intranasal glucagon, compared to placebo, was evaluated by measuring serum GH (µg/L) at baseline (0 minutes) and after 45 minutes from glucagon/placebo administration.

  22. Change in serum GH levels between baseline and 60 minutes after glucagon/placebo administration

    Time frame: From baseline (0 minutes) to 60 minutes after glucagon/placebo administration

    The response of the somatotroph axis to the administration of intranasal glucagon, compared to placebo, was evaluated by measuring serum GH (µg/L) at baseline (0 minutes) and after 60 minutes from glucagon/placebo administration.

  23. Change in serum GH levels between baseline and 75 minutes after glucagon/placebo administration

    Time frame: From baseline (0 minutes) to 75 minutes after glucagon/placebo administration

    The response of the somatotroph axis to the administration of intranasal glucagon, compared to placebo, was evaluated by measuring serum GH (µg/L) at baseline (0 minutes) and after 75 minutes from glucagon/placebo administration.

  24. Change in serum GH levels between baseline and 90 minutes after glucagon/placebo administration

    Time frame: From baseline (0 minutes) to 90 minutes after glucagon/placebo administration

    The response of the somatotroph axis to the administration of intranasal glucagon, compared to placebo, was evaluated by measuring serum GH (µg/L) at baseline (0 minutes) and after 90 minutes from glucagon/placebo administration.

  25. Change in serum GH levels between baseline and 120 minutes after glucagon/placebo administration

    Time frame: From baseline (0 minutes) to 120 minutes after glucagon/placebo administration

    The response of the somatotroph axis to the administration of intranasal glucagon, compared to placebo, was evaluated by measuring serum GH (µg/L) at baseline (0 minutes) and after 120 minutes from glucagon/placebo administration.

  26. Change in serum GH levels between baseline and 150 minutes after glucagon/placebo administration

    Time frame: From baseline (0 minutes) to 150 minutes after glucagon/placebo administration

    The response of the somatotroph axis to the administration of intranasal glucagon, compared to placebo, was evaluated by measuring serum GH (µg/L) at baseline (0 minutes) and after 150 minutes from glucagon/placebo administration.

  27. Change in serum GH levels between baseline and 180 minutes after glucagon/placebo administration

    Time frame: From baseline (0 minutes) to 180 minutes after glucagon/placebo administration

    The response of the somatotroph axis to the administration of intranasal glucagon, compared to placebo, was evaluated by measuring serum GH (µg/L) at baseline (0 minutes) and after 180 minutes from glucagon/placebo administration.

  28. Change in plasma copeptin levels between baseline and 15 minutes after glucagon/placebo administration

    Time frame: From baseline (0 minutes) to 15 minutes after glucagon/placebo administration

    The response of the antidiuretic axis to the administration of intranasal glucagon, compared to placebo, was evaluated by measuring plasma copeptin (pmol/L) at baseline (0 minutes) and after 15 minutes from glucagon/placebo administration.

  29. Change in plasma copeptin levels between baseline and 30 minutes after glucagon/placebo administration

    Time frame: From baseline (0 minutes) to 30 minutes after glucagon/placebo administration

    The response of the antidiuretic axis to the administration of intranasal glucagon, compared to placebo, was evaluated by measuring plasma copeptin (pmol/L) at baseline (0 minutes) and after 30 minutes from glucagon/placebo administration.

  30. Change in plasma copeptin levels between baseline and 45 minutes after glucagon/placebo administration

    Time frame: From baseline (0 minutes) to 45 minutes after glucagon/placebo administration

    The response of the antidiuretic axis to the administration of intranasal glucagon, compared to placebo, was evaluated by measuring plasma copeptin (pmol/L) at baseline (0 minutes) and after 45 minutes from glucagon/placebo administration.

  31. Change in plasma copeptin levels between baseline and 60 minutes after glucagon/placebo administration

    Time frame: From baseline (0 minutes) to 60 minutes after glucagon/placebo administration

    The response of the antidiuretic axis to the administration of intranasal glucagon, compared to placebo, was evaluated by measuring plasma copeptin (pmol/L) at baseline (0 minutes) and after 60 minutes from glucagon/placebo administration.

  32. Change in plasma copeptin levels between baseline and 75 minutes after glucagon/placebo administration

    Time frame: From baseline (0 minutes) to 75 minutes after glucagon/placebo administration

    The response of the antidiuretic axis to the administration of intranasal glucagon, compared to placebo, was evaluated by measuring plasma copeptin (pmol/L) at baseline (0 minutes) and after 75 minutes from glucagon/placebo administration.

  33. Change in plasma copeptin levels between baseline and 90 minutes after glucagon/placebo administration

    Time frame: From baseline (0 minutes) to 90 minutes after glucagon/placebo administration

    The response of the antidiuretic axis to the administration of intranasal glucagon, compared to placebo, was evaluated by measuring plasma copeptin (pmol/L) at baseline (0 minutes) and after 90 minutes from glucagon/placebo administration.

  34. Change in plasma copeptin levels between baseline and 120 minutes after glucagon/placebo administration

    Time frame: From baseline (0 minutes) to 120 minutes after glucagon/placebo administration

    The response of the antidiuretic axis to the administration of intranasal glucagon, compared to placebo, was evaluated by measuring plasma copeptin (pmol/L) at baseline (0 minutes) and after 120 minutes from glucagon/placebo administration.

  35. Change in plasma copeptin levels between baseline and 150 minutes after glucagon/placebo administration

    Time frame: From baseline (0 minutes) to 150 minutes after glucagon/placebo administration

    The response of the antidiuretic axis to the administration of intranasal glucagon, compared to placebo, was evaluated by measuring plasma copeptin (pmol/L) at baseline (0 minutes) and after 150 minutes from glucagon/placebo administration.

  36. Change in plasma copeptin levels between baseline and 180 minutes after glucagon/placebo administration

    Time frame: From baseline (0 minutes) to 180 minutes after glucagon/placebo administration

    The response of the antidiuretic axis to the administration of intranasal glucagon, compared to placebo, was evaluated by measuring plasma copeptin (pmol/L) at baseline (0 minutes) and after 180 minutes from glucagon/placebo administration.

Secondary outcomes

  1. Change in serum sodium levels between baseline and 15 minutes after glucagon/placebo administration

    Time frame: From baseline (0 minutes) to 15 minutes after glucagon/placebo administration

    The response to the administration of intranasal glucagon, compared to placebo, in terms of glycometabolic and hydro-electrolyte biochemical balance was evaluated by measuring serum sodium (mmol/L) at baseline (0 minutes) and after 15 minutes from glucagon/placebo administration.

  2. Change in serum sodium levels between baseline and 30 minutes after glucagon/placebo administration

    Time frame: From baseline (0 minutes) to 30 minutes after glucagon/placebo administration

    The response to the administration of intranasal glucagon, compared to placebo, in terms of glycometabolic and hydro-electrolyte biochemical balance was evaluated by measuring serum sodium (mmol/L) at baseline (0 minutes) and after 30 minutes from glucagon/placebo administration.

  3. Change in serum sodium levels between baseline and 45 minutes after glucagon/placebo administration

    Time frame: From baseline (0 minutes) to 45 minutes after glucagon/placebo administration

    The response to the administration of intranasal glucagon, compared to placebo, in terms of glycometabolic and hydro-electrolyte biochemical balance was evaluated by measuring serum sodium (mmol/L) at baseline (0 minutes) and after 45 minutes from glucagon/placebo administration.

  4. Change in serum sodium levels between baseline and 60 minutes after glucagon/placebo administration

    Time frame: From baseline (0 minutes) to 60 minutes after glucagon/placebo administration

    The response to the administration of intranasal glucagon, compared to placebo, in terms of glycometabolic and hydro-electrolyte biochemical balance was evaluated by measuring serum sodium (mmol/L) at baseline (0 minutes) and after 60 minutes from glucagon/placebo administration.

  5. Change in serum sodium levels between baseline and 75 minutes after glucagon/placebo administration

    Time frame: From baseline (0 minutes) to 75 minutes after glucagon/placebo administration

    The response to the administration of intranasal glucagon, compared to placebo, in terms of glycometabolic and hydro-electrolyte biochemical balance was evaluated by measuring serum sodium (mmol/L) at baseline (0 minutes) and after 75 minutes from glucagon/placebo administration.

  6. Change in serum sodium levels between baseline and 90 minutes after glucagon/placebo administration

    Time frame: From baseline (0 minutes) to 90 minutes after glucagon/placebo administration

    The response to the administration of intranasal glucagon, compared to placebo, in terms of glycometabolic and hydro-electrolyte biochemical balance was evaluated by measuring serum sodium (mmol/L) at baseline (0 minutes) and after 90 minutes from glucagon/placebo administration.

  7. Change in serum sodium levels between baseline and 120 minutes after glucagon/placebo administration

    Time frame: From baseline (0 minutes) to 120 minutes after glucagon/placebo administration

    The response to the administration of intranasal glucagon, compared to placebo, in terms of glycometabolic and hydro-electrolyte biochemical balance was evaluated by measuring serum sodium (mmol/L) at baseline (0 minutes) and after 120 minutes from glucagon/placebo administration.

  8. Change in serum sodium levels between baseline and 150 minutes after glucagon/placebo administration

    Time frame: From baseline (0 minutes) to 150 minutes after glucagon/placebo administration

    The response to the administration of intranasal glucagon, compared to placebo, in terms of glycometabolic and hydro-electrolyte biochemical balance was evaluated by measuring serum sodium (mmol/L) at baseline (0 minutes) and after 150 minutes from glucagon/placebo administration.

  9. Change in serum sodium levels between baseline and 180 minutes after glucagon/placebo administration

    Time frame: From baseline (0 minutes) to 180 minutes after glucagon/placebo administration

    The response to the administration of intranasal glucagon, compared to placebo, in terms of glycometabolic and hydro-electrolyte biochemical balance was evaluated by measuring serum sodium (mmol/L) at baseline (0 minutes) and after 180 minutes from glucagon/placebo administration.

  10. Change in serum potassium levels between baseline and 15 minutes after glucagon/placebo administration

    Time frame: From baseline (0 minutes) to 15 minutes after glucagon/placebo administration

    The response to the administration of intranasal glucagon, compared to placebo, in terms of glycometabolic and hydro-electrolyte biochemical balance was evaluated by measuring serum potassium (mmol/L) at baseline (0 minutes) and after 15 minutes from glucagon/placebo administration.

  11. Change in serum potassium levels between baseline and 30 minutes after glucagon/placebo administration

    Time frame: From baseline (0 minutes) to 30 minutes after glucagon/placebo administration

    The response to the administration of intranasal glucagon, compared to placebo, in terms of glycometabolic and hydro-electrolyte biochemical balance was evaluated by measuring serum potassium (mmol/L) at baseline (0 minutes) and after 30 minutes from glucagon/placebo administration.

  12. Change in serum potassium levels between baseline and 45 minutes after glucagon/placebo administration

    Time frame: From baseline (0 minutes) to 45 minutes after glucagon/placebo administration

    The response to the administration of intranasal glucagon, compared to placebo, in terms of glycometabolic and hydro-electrolyte biochemical balance was evaluated by measuring serum potassium (mmol/L) at baseline (0 minutes) and after 45 minutes from glucagon/placebo administration.

  13. Change in serum potassium levels between baseline and 60 minutes after glucagon/placebo administration

    Time frame: From baseline (0 minutes) to 60 minutes after glucagon/placebo administration

    The response to the administration of intranasal glucagon, compared to placebo, in terms of glycometabolic and hydro-electrolyte biochemical balance was evaluated by measuring serum potassium (mmol/L) at baseline (0 minutes) and after 60 minutes from glucagon/placebo administration.

  14. Change in serum potassium levels between baseline and 75 minutes after glucagon/placebo administration

    Time frame: From baseline (0 minutes) to 75 minutes after glucagon/placebo administration

    The response to the administration of intranasal glucagon, compared to placebo, in terms of glycometabolic and hydro-electrolyte biochemical balance was evaluated by measuring serum potassium (mmol/L) at baseline (0 minutes) and after 75 minutes from glucagon/placebo administration.

  15. Change in serum potassium levels between baseline and 90 minutes after glucagon/placebo administration

    Time frame: From baseline (0 minutes) to 90 minutes after glucagon/placebo administration

    The response to the administration of intranasal glucagon, compared to placebo, in terms of glycometabolic and hydro-electrolyte biochemical balance was evaluated by measuring serum potassium (mmol/L) at baseline (0 minutes) and after 90 minutes from glucagon/placebo administration.

  16. Change in serum potassium levels between baseline and 120 minutes after glucagon/placebo administration

    Time frame: From baseline (0 minutes) to 120 minutes after glucagon/placebo administration

    The response to the administration of intranasal glucagon, compared to placebo, in terms of glycometabolic and hydro-electrolyte biochemical balance was evaluated by measuring serum potassium (mmol/L) at baseline (0 minutes) and after 120 minutes from glucagon/placebo administration.

  17. Change in serum potassium levels between baseline and 150 minutes after glucagon/placebo administration

    Time frame: From baseline (0 minutes) to 150 minutes after glucagon/placebo administration

    The response to the administration of intranasal glucagon, compared to placebo, in terms of glycometabolic and hydro-electrolyte biochemical balance was evaluated by measuring serum potassium (mmol/L) at baseline (0 minutes) and after 150 minutes from glucagon/placebo administration.

  18. Change in serum potassium levels between baseline and 180 minutes after glucagon/placebo administration

    Time frame: From baseline (0 minutes) to 180 minutes after glucagon/placebo administration

    The response to the administration of intranasal glucagon, compared to placebo, in terms of glycometabolic and hydro-electrolyte biochemical balance was evaluated by measuring serum potassium (mmol/L) at baseline (0 minutes) and after 180 minutes from glucagon/placebo administration.

  19. Change in plasma osmolality between baseline and 15 minutes after glucagon/placebo administration

    Time frame: From baseline (0 minutes) to 15 minutes after glucagon/placebo administration

    The response to the administration of intranasal glucagon, compared to placebo, in terms of glycometabolic and hydro-electrolyte biochemical balance was evaluated by measuring plasma osmolality (mOsm/kg) at baseline (0 minutes) and after 15 minutes from glucagon/placebo administration.

  20. Change in plasma osmolality between baseline and 30 minutes after glucagon/placebo administration

    Time frame: From baseline (0 minutes) to 30 minutes after glucagon/placebo administration

    The response to the administration of intranasal glucagon, compared to placebo, in terms of glycometabolic and hydro-electrolyte biochemical balance was evaluated by measuring plasma osmolality (mOsm/kg) at baseline (0 minutes) and after 30 minutes from glucagon/placebo administration.

  21. Change in plasma osmolality between baseline and 45 minutes after glucagon/placebo administration

    Time frame: From baseline (0 minutes) to 45 minutes after glucagon/placebo administration

    The response to the administration of intranasal glucagon, compared to placebo, in terms of glycometabolic and hydro-electrolyte biochemical balance was evaluated by measuring plasma osmolality (mOsm/kg) at baseline (0 minutes) and after 45 minutes from glucagon/placebo administration.

  22. Change in plasma osmolality between baseline and 60 minutes after glucagon/placebo administration

    Time frame: From baseline (0 minutes) to 60 minutes after glucagon/placebo administration

    The response to the administration of intranasal glucagon, compared to placebo, in terms of glycometabolic and hydro-electrolyte biochemical balance was evaluated by measuring plasma osmolality (mOsm/kg) at baseline (0 minutes) and after 60 minutes from glucagon/placebo administration.

  23. Change in plasma osmolality between baseline and 75 minutes after glucagon/placebo administration

    Time frame: From baseline (0 minutes) to 75 minutes after glucagon/placebo administration

    The response to the administration of intranasal glucagon, compared to placebo, in terms of glycometabolic and hydro-electrolyte biochemical balance was evaluated by measuring plasma osmolality (mOsm/kg) at baseline (0 minutes) and after 75 minutes from glucagon/placebo administration.

  24. Change in plasma osmolality between baseline and 90 minutes after glucagon/placebo administration

    Time frame: From baseline (0 minutes) to 90 minutes after glucagon/placebo administration

    The response to the administration of intranasal glucagon, compared to placebo, in terms of glycometabolic and hydro-electrolyte biochemical balance was evaluated by measuring plasma osmolality (mOsm/kg) at baseline (0 minutes) and after 90 minutes from glucagon/placebo administration.

  25. Change in plasma osmolality between baseline and 120 minutes after glucagon/placebo administration

    Time frame: From baseline (0 minutes) to 120 minutes after glucagon/placebo administration

    The response to the administration of intranasal glucagon, compared to placebo, in terms of glycometabolic and hydro-electrolyte biochemical balance was evaluated by measuring plasma osmolality (mOsm/kg) at baseline (0 minutes) and after 120 minutes from glucagon/placebo administration.

  26. Change in plasma osmolality between baseline and 150 minutes after glucagon/placebo administration

    Time frame: From baseline (0 minutes) to 150 minutes after glucagon/placebo administration

    The response to the administration of intranasal glucagon, compared to placebo, in terms of glycometabolic and hydro-electrolyte biochemical balance was evaluated by measuring plasma osmolality (mOsm/kg) at baseline (0 minutes) and after 150 minutes from glucagon/placebo administration.

  27. Change in plasma osmolality between baseline and 180 minutes after glucagon/placebo administration

    Time frame: From baseline (0 minutes) to 180 minutes after glucagon/placebo administration

    The response to the administration of intranasal glucagon, compared to placebo, in terms of glycometabolic and hydro-electrolyte biochemical balance was evaluated by measuring plasma osmolality (mOsm/kg) at baseline (0 minutes) and after 180 minutes from glucagon/placebo administration.

  28. Change in serum glucose levels between baseline and 15 minutes after glucagon/placebo administration

    Time frame: From baseline (0 minutes) to 15 minutes after glucagon/placebo administration

    The response to the administration of intranasal glucagon, compared to placebo, in terms of glycometabolic and hydro-electrolyte biochemical balance was evaluated by measuring serum glucose (mg/dl) at baseline (0 minutes) and after 15 minutes from glucagon/placebo administration.

  29. Change in serum glucose levels between baseline and 30 minutes after glucagon/placebo administration

    Time frame: From baseline (0 minutes) to 30 minutes after glucagon/placebo administration

    The response to the administration of intranasal glucagon, compared to placebo, in terms of glycometabolic and hydro-electrolyte biochemical balance was evaluated by measuring serum glucose (mg/dl) at baseline (0 minutes) and after 30 minutes from glucagon/placebo administration.

  30. Change in serum glucose levels between baseline and 45 minutes after glucagon/placebo administration

    Time frame: From baseline (0 minutes) to 45 minutes after glucagon/placebo administration

    The response to the administration of intranasal glucagon, compared to placebo, in terms of glycometabolic and hydro-electrolyte biochemical balance was evaluated by measuring serum glucose (mg/dl) at baseline (0 minutes) and after 45 minutes from glucagon/placebo administration.

  31. Change in serum glucose levels between baseline and 60 minutes after glucagon/placebo administration

    Time frame: From baseline (0 minutes) to 60 minutes after glucagon/placebo administration

    The response to the administration of intranasal glucagon, compared to placebo, in terms of glycometabolic and hydro-electrolyte biochemical balance was evaluated by measuring serum glucose (mg/dl) at baseline (0 minutes) and after 60 minutes from glucagon/placebo administration.

  32. Change in serum glucose levels between baseline and 75 minutes after glucagon/placebo administration

    Time frame: From baseline (0 minutes) to 75 minutes after glucagon/placebo administration

    The response to the administration of intranasal glucagon, compared to placebo, in terms of glycometabolic and hydro-electrolyte biochemical balance was evaluated by measuring serum glucose (mg/dl) at baseline (0 minutes) and after 75 minutes from glucagon/placebo administration.

  33. Change in serum glucose levels between baseline and 90 minutes after glucagon/placebo administration

    Time frame: From baseline (0 minutes) to 90 minutes after glucagon/placebo administration

    The response to the administration of intranasal glucagon, compared to placebo, in terms of glycometabolic and hydro-electrolyte biochemical balance was evaluated by measuring serum glucose (mg/dl) at baseline (0 minutes) and after 90 minutes from glucagon/placebo administration.

  34. Change in serum glucose levels between baseline and 120 minutes after glucagon/placebo administration

    Time frame: From baseline (0 minutes) to 120 minutes after glucagon/placebo administration

    The response to the administration of intranasal glucagon, compared to placebo, in terms of glycometabolic and hydro-electrolyte biochemical balance was evaluated by measuring serum glucose (mg/dl) at baseline (0 minutes) and after 120 minutes from glucagon/placebo administration.

  35. Change in serum glucose levels between baseline and 150 minutes after glucagon/placebo administration

    Time frame: From baseline (0 minutes) to 150 minutes after glucagon/placebo administration

    The response to the administration of intranasal glucagon, compared to placebo, in terms of glycometabolic and hydro-electrolyte biochemical balance was evaluated by measuring serum glucose (mg/dl) at baseline (0 minutes) and after 150 minutes from glucagon/placebo administration.

  36. Change in serum glucose levels between baseline and 180 minutes after glucagon/placebo administration

    Time frame: From baseline (0 minutes) to 180 minutes after glucagon/placebo administration

    The response to the administration of intranasal glucagon, compared to placebo, in terms of glycometabolic and hydro-electrolyte biochemical balance was evaluated by measuring serum glucose (mg/dl) at baseline (0 minutes) and after 180 minutes from glucagon/placebo administration.

  37. Change in plasma insulin levels between baseline and 15 minutes after glucagon/placebo administration

    Time frame: From baseline (0 minutes) to 15 minutes after glucagon/placebo administration

    The response to the administration of intranasal glucagon, compared to placebo, in terms of glycometabolic and hydro-electrolyte biochemical balance was evaluated by measuring plasma insulin (mU/L) at baseline (0 minutes) and after 15 minutes from glucagon/placebo administration.

  38. Change in plasma insulin levels between baseline and 30 minutes after glucagon/placebo administration

    Time frame: From baseline (0 minutes) to 30 minutes after glucagon/placebo administration

    The response to the administration of intranasal glucagon, compared to placebo, in terms of glycometabolic and hydro-electrolyte biochemical balance was evaluated by measuring plasma insulin (mU/L) at baseline (0 minutes) and after 30 minutes from glucagon/placebo administration.

  39. Change in plasma insulin levels between baseline and 45 minutes after glucagon/placebo administration

    Time frame: From baseline (0 minutes) to 45 minutes after glucagon/placebo administration

    The response to the administration of intranasal glucagon, compared to placebo, in terms of glycometabolic and hydro-electrolyte biochemical balance was evaluated by measuring plasma insulin (mU/L) at baseline (0 minutes) and after 45 minutes from glucagon/placebo administration.

  40. Change in plasma insulin levels between baseline and 60 minutes after glucagon/placebo administration

    Time frame: From baseline (0 minutes) to 60 minutes after glucagon/placebo administration

    The response to the administration of intranasal glucagon, compared to placebo, in terms of glycometabolic and hydro-electrolyte biochemical balance was evaluated by measuring plasma insulin (mU/L) at baseline (0 minutes) and after 60 minutes from glucagon/placebo administration.

  41. Change in plasma insulin levels between baseline and 75 minutes after glucagon/placebo administration

    Time frame: From baseline (0 minutes) to 75 minutes after glucagon/placebo administration

    The response to the administration of intranasal glucagon, compared to placebo, in terms of glycometabolic and hydro-electrolyte biochemical balance was evaluated by measuring plasma insulin (mU/L) at baseline (0 minutes) and after 75 minutes from glucagon/placebo administration.

  42. Change in plasma insulin levels between baseline and 90 minutes after glucagon/placebo administration

    Time frame: From baseline (0 minutes) to 90 minutes after glucagon/placebo administration

    The response to the administration of intranasal glucagon, compared to placebo, in terms of glycometabolic and hydro-electrolyte biochemical balance was evaluated by measuring plasma insulin (mU/L) at baseline (0 minutes) and after 90 minutes from glucagon/placebo administration.

  43. Change in plasma insulin levels between baseline and 120 minutes after glucagon/placebo administration

    Time frame: From baseline (0 minutes) to 120 minutes after glucagon/placebo administration

    The response to the administration of intranasal glucagon, compared to placebo, in terms of glycometabolic and hydro-electrolyte biochemical balance was evaluated by measuring plasma insulin (mU/L) at baseline (0 minutes) and after 120 minutes from glucagon/placebo administration.

  44. Change in plasma insulin levels between baseline and 150 minutes after glucagon/placebo administration

    Time frame: From baseline (0 minutes) to 150 minutes after glucagon/placebo administration

    The response to the administration of intranasal glucagon, compared to placebo, in terms of glycometabolic and hydro-electrolyte biochemical balance was evaluated by measuring plasma insulin (mU/L) at baseline (0 minutes) and after 150 minutes from glucagon/placebo administration.

  45. Change in plasma insulin levels between baseline and 180 minutes after glucagon/placebo administration

    Time frame: From baseline (0 minutes) to 180 minutes after glucagon/placebo administration

    The response to the administration of intranasal glucagon, compared to placebo, in terms of glycometabolic and hydro-electrolyte biochemical balance was evaluated by measuring plasma insulin (mU/L) at baseline (0 minutes) and after 180 minutes from glucagon/placebo administration.

  46. Change in urine sodium levels between baseline and 180 minutes after glucagon/placebo administration

    Time frame: From baseline (0 minutes) to 180 minutes after glucagon/placebo administration

    The response to the administration of intranasal glucagon, compared to placebo, in terms of glycometabolic and hydro-electrolyte biochemical balance was evaluated by measuring urine sodium (mmol/L) at baseline (0 minutes) and after 180 minutes from glucagon/placebo administration.

  47. Change in urine potassium levels between baseline and 180 minutes after glucagon/placebo administration

    Time frame: From baseline (0 minutes) to 180 minutes after glucagon/placebo administration

    The response to the administration of intranasal glucagon, compared to placebo, in terms of glycometabolic and hydro-electrolyte biochemical balance was evaluated by measuring urine potassium (mmol/L) at baseline (0 minutes) and after 180 minutes from glucagon/placebo administration.

  48. Change in urine creatinine levels between baseline and 180 minutes after glucagon/placebo administration

    Time frame: From baseline (0 minutes) to 180 minutes after glucagon/placebo administration

    The response to the administration of intranasal glucagon, compared to placebo, in terms of glycometabolic and hydro-electrolyte biochemical balance was evaluated by measuring urine creatinine (mg/dl) at baseline (0 minutes) and after 180 minutes from glucagon/placebo administration.

  49. Change in urine osmolality between baseline and 180 minutes after glucagon/placebo administration

    Time frame: From baseline (0 minutes) to 180 minutes after glucagon/placebo administration

    The response to the administration of intranasal glucagon, compared to placebo, in terms of glycometabolic and hydro-electrolyte biochemical balance was evaluated by measuring urine osmolality (mOsm/kg) at baseline (0 minutes) and after 180 minutes from glucagon/placebo administration.

  50. Change in resistance at bioimpedance vector analysis between baseline and 180 minutes after glucagon/placebo administration

    Time frame: From baseline (0 minutes) to 180 minutes after glucagon/placebo administration

    The response to the administration of intranasal glucagon, compared to placebo, in terms of bioimpedance vector analysis (BIVA) was evaluated by measuring resistance (Ohm) at baseline (0 minutes) and after 180 minutes from glucagon/placebo administration.

  51. Change in reactance at bioimpedance vector analysis between baseline and 180 minutes after glucagon/placebo administration

    Time frame: From baseline (0 minutes) to 180 minutes after glucagon/placebo administration

    The response to the administration of intranasal glucagon, compared to placebo, in terms of bioimpedance vector analysis (BIVA) was evaluated by measuring reactance (Ohm) at baseline (0 minutes) and after 180 minutes from glucagon/placebo administration.

  52. Change in phase angle at bioimpedance vector analysis between baseline and 180 minutes after glucagon/placebo administration

    Time frame: From baseline (0 minutes) to 180 minutes after glucagon/placebo administration

    The response to the administration of intranasal glucagon, compared to placebo, in terms of bioimpedance vector analysis (BIVA) was evaluated by measuring phase angle (°) at baseline (0 minutes) and after 180 minutes from glucagon/placebo administration.

Sponsors and collaborators

Lead sponsor

A.O.U. Città della Salute e della Scienza

Other

Registry information

Important dates

Study start
2021
Primary completion
2021
Study completion
2021
First posted
Jan 25, 2022
Registry last updated
Jan 25, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.